Drug Profile
Glasdegib - Pfizer
Alternative Names: 1095173-27-5; DAURISMO; PF 04; PF-04449913; PF-4449913Latest Information Update: 25 Jan 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Grupo Espanol de Trasplante Hematopoyetico y Terapia Celular; H. Lee Moffitt Cancer Center and Research Institute; Pfizer; Yale University
- Class Antineoplastics; Benzimidazoles; Phenylurea compounds; Piperidines; Small molecules
- Mechanism of Action Hedgehog cell-signalling pathway inhibitors; SMO protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Acute myeloid leukaemia
- Phase II Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Myelofibrosis
- Phase I/II Glioblastoma; Graft-versus-host disease
- No development reported Cancer; Haematological malignancies; Solid tumours
Most Recent Events
- 28 Dec 2023 Pfizer completes the phase I trial in Haematological-malignancies (Late-stage disease, Monotherapy, Second-line therapy or greater), Acute-myeloid-leukaemia (Combination therapy, First-line therapy), Myelodysplastic-syndromes (Combination therapy, First-line therapy) in Japan (NCT02038777)
- 29 Nov 2023 Grupo Espanol in collaboration with Pfizer completes a phase Ib/II GEINOGLAS trial for Glioblastoma (Combination therapy, First-line therapy) in Spain (PO) (NCT03466450) (EudraCT2017-002410-31)
- 20 Oct 2023 Efficacy data from a phase Ib/II GEINOGLAS trial in Glioblastoma presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)